Глобальный рынок лечения мультиформной глиобластомы — тенденции отрасли и прогноз до 2029 года

Анализ рынка и идеи

Мультиформная глиобластома (GBM) — злокачественная опухоль IV степени злокачественности по классификации ВОЗ с астроцитарной дифференцировкой. Как одна из наиболее распространенных клинически диагностируемых онкологических записей центральной нервной системы (ЦНС), существует множество исторических отчетов об описании и развитии идей относительно этих опухолей. Первые зарегистрированные отчеты о глиомах были даны в британских научных отчетах Бернсом в 1800 году и Абернети в 1804 году, а первое всеобъемлющее гистоморфологическое описание было дано в 1865 году Рудольфом Вирховым. В 1926 году Персиваль Бейли и Харви Кушинг заложили основу для современной классификации глиом. В период с 1934 по 1941 год самым плодовитым исследователем в области изучения глиом был Ганс-Иоахим Шерер, который постулировал некоторые клинико-морфологические аспекты GBM. С введением молекулярных и генетических тестов была установлена ​​истинная многоформность GBM, при этом различные генотипы имеют одинаковую гистоморфологическую и IHC картину, а также некоторые аспекты глиомагенеза. Для развития GBM в стволовой клетке GBM должна произойти определенная триггерная мутация — первичная GBM, или медленная агрегация отдельных мутаций без четкой триггерной мутации — вторичная GBM. Знание GBM тесно связано с общими медицинскими знаниями о ЦНС, поскольку эти злокачественные новообразования были впервые описаны более 200 лет назад. За это время было сделано несколько больших скачков, как в области ЦНС, так и в области общих медицинских знаний. Растет спрос на лечение мультиформной глиобластомы, для чего производители участвуют в запуске новых продуктов, увеличении линейки продуктов и участии в мероприятиях на рынке. Эти решения в конечном итоге усиливают рост рынка. 

The glioblastoma multiforme treatment market report provides details of market share, new developments, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing  of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.

The glioblastoma multiforme treatment market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that  glioblastoma multiforme treatment market will grow at a CAGR of 8.1% during the forecast period of 2022 to 2029.

Market Definition

Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor and accounts for 60% of brain tumors in adults. GBMs can arise in the brain de novo or evolve from lower-grade astrocytoma. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. Many genetic and environmental factors have been studied in glioblastoma multiforme, but no risk factor that accounts for a large proportion of GBM has been identified. So like many other cancers, GBM is sporadic, although some studies indicate a high prevalence (17%) of prior therapeutic irradiation among patients with GBM. The latency between irradiation and the development of GBM varies from a few years to several decades. There is no substantial evidence of GBM association with lifestyle factors like smoking, alcohol consumption, drug use, or exposure to N- Nitroso compounds. Studies have shown that the use of mobile phones doesn't increase the risk of development of GBM; however, its association with long term use needs further confirmation.                               

Global Glioblastoma Multiforme Treatment Market Dynamics

Drivers

• Growing prevalence of glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most commonly occurring malignant primary brain tumor, representing 77%-81% of all central nervous system (CNS) primary malignant tumors. The World Health Organization classified it as a grade IV diffuse astrocytic and oligodendroglial tumor. The mean age of primary GBM presentation is 62 years, and the median survival is approximately 14.6 months. The poor prognosis associated with GBM is well documented, while survival rates remain disappointingly low despite medical and surgical advances. As per the study, International studies reveal an approximate annual incidence rate of 0.59 to 5 per 100,000 persons; however, studies indicate a rise in incidence. Miranda-Filho et al. in 2017 described increasing rates of CNS and brain cancers in countries in South America, Eastern Europe, and Southern Europe, while decreasing rates were only reported in Japan. Dobes et al. in 2011 have also noted an increasing incidence of GBM tumors in two of their multicentered Australian studies, with a particular increase in frontal and temporal lobe GBM tumors. The increased incidence of glioblastoma multiforme raises the demand for early detection and diagnosis via utilizing the latest technology, propelling the global glioblastoma multiforme treatment market. The rising incidence of glioblastoma across the globe is expected to accelerate the demand for glioblastoma multiforme treatment. Thus, the increased incidence rates of glioblastoma multiforme are expected to boost the market's growth.

• Increasing research and development (R&D)

Increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. Tumor heterogeneity and variation in the patient-to-patient treatment approach are expected to increase the demand for a personalized treatment approach to manage glioblastoma  multiforme. The approval of new treatments is expected to increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, a special designation granted to investigational drugs by the FDA is expected to expedite novel therapy's approval process and commercialization. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme. The increasing approval for novel therapy and combination therapy is expected to drive the glioblastoma multiforme treatment market. 

Opportunity

• Increasing drug approvals

The escalating demand for glioblastoma multiforme treatment should yield more regulatory approvals for associated drugs. Increasing regulatory endorsements for related drugs and recombinant products will constitute an increase in glioblastoma multiforme treatment market value in the coming years. In the framework of a Pan American Health Organization (PAHO) initiative to promote the recognition of Drug Regulatory Authorities, ANMAT´s evaluation process finished on December 11, 2009. The glioblastoma multiforme treatment industry has witnessed numerous drug approvals in recent years, driven by the increasing fatality rate of the disease. Increasing drug approvals will ramp up the glioblastoma multiforme treatment market demand.

Restraints/Challenges

High cost of glioblastoma multiforme treatment

The diagnostic tests for glioblastoma multiforme include highly technologically advanced products. Developing those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing.

The diagnostic tools and techniques used for the diagnosis of glioblastoma multiforme include

radiation therapy, chemotherapy, among others. Early stages of GBM typically present with minimal or no symptoms; therefore, GBM is frequently diagnosed at advanced stages, resulting in a poor prognosis. Thus, the high cost of treating the glioblastoma multiforme using the advanced modalities and technology products will act as a major restraining factor for the growth of the global glioblastoma multiforme treatment market.

Recent Developments

• In April 2022, Elekta and GE Healthcare announced that they had signed a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. This partnership will allow the companies to jointly promote solutions for each cancer center’s needs
• In July 2019, Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) is available in the United States (U.S.). This launch will enhance the sales of the product in the region

Glioblastoma Multiforme Treatment Market Scope

The glioblastoma multiforme treatment market is categorized into seven notable segments which are based on type, treatment, patient type, drug type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

• Primary (De Novo)
• Secondary

On the basis of  type, the glioblastoma multiforme treatment market is segmented into primary (De Novo) and secondary.

Treatment

• Surgery
• Radiotherapy
• Medications

On the basis of treatment, the glioblastoma multiforme treatment market is segmented into surgery, radiotherapy and medications.

Patient Type

• Adult
• Geriatric
• Child

On the basis of patient type, the glioblastoma multiforme treatment market is segmented into adult, geriatric and child.

Drug Type

• Branded
• Generics

On the basis of drug type, the glioblastoma multiforme treatment market is segmented into generics and branded.

Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the glioblastoma multiforme treatment market is segmented into parenteral, oral and others.

End User

• Hospitals
• Clinics
• Home Healthcare
• Others

On the basis of end user, the glioblastoma multiforme treatment market is segmented into hospitals, clinics, home healthcare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the glioblastoma multiforme treatment market is segmented into hospital pharmacy, retail pharmacy and others.

Global Glioblastoma Multiforme Treatment Market Regional Analysis/Insights

The glioblastoma multiforme treatment market is analysed and market size insights and trends are provided by type, treatment, patient type, drug type, route of administration, end user and distribution channel as referenced above.

The regions covered in the glioblastoma multiforme treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina, Peru and Rest of South America as part of South America.

In North America, the U.S. is expected to dominate the market due to the increasing prevalence of the disease in the region. Germany is expected to dominate the European market due to the large number of major market players. Japan is expected to dominate the Asia-Pacific market due to the increased research and development activities in the country.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Glioblastoma Multiforme Treatment Market Share Analysis

The glioblastoma multiforme treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on glioblastoma multiforme treatment market.

Некоторые из ключевых игроков на рынке: F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc. (дочерняя компания Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC. (дочерняя компания Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (дочерняя компания Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc. и Zydus Pharmaceuticals, Inc. и другие.

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщиков. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.

SKU-56264